News
| 2 min read
University of Arizona researcher looks beyond traditional causes to find novel therapies
| 2 min read
InteRNA publishes preclinical data from investigational microRNA program
| 2 min read
Asher Bio focuses on cis-targeting technology to precisely target discrete immune cell subtypes
| 2 min read
AzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency
| 3 min read
Positive top-line Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis
| 2 min read
Italfarmaco publishes positive long-term data for givinostat in polycythemia vera patients
| 5 min read
Trying to overcome misinterpretations of the Supreme Court's decisions on patent eligibility by district courts and the Federal Circuit
| 2 min read
Algernon Pharmaceuticals submits pre-IND meeting request for clinical research program in DMT for stroke
| 2 min read
Roche will acquire the California-based diagnostics company for $1.8 billion
| 2 min read
Altimmune's AdCOVID vaccine candidate performs well in preclinical models
| 4 min read
High tumor mutation burden can predict immunotherapy response only in subset of cancers
| 2 min read
IntelGenx announces strategic partnership with atai Life Sciences; agreement also includes equity investment by atai
